Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 6 months post-acquired brain injury~* Male or female subjects, at least 18 years of age~* Independent ambulation with or without assistive device or orthotic device~* Cognitive Rancho Level VI or higher, ability to follow directions, and likely to complete all required visits~* At least 100 degrees of passive knee flexion ROM~* Gait velocity greater than or equal to 0.4 m/sec~* Modified Ashworth scale rating of 1+ or higher for RF spasticity~* Written informed consent and/or assent has been obtained~* Meet criteria for stiff knee gait based on baseline computerized gait analysis data less than 2 weeks prior to receiving intervention, including:~  * Peak knee flexion less than or equal to 50 degrees (or \> 2 standard deviations below normal adult peak knee flexion)~ * Peak knee flexion velocity less than or equal to 256 degrees/% gait cycle (or \> 2 standard deviations below normal peak knee flexion velocity)~Exclusion Criteria:~* Change in spasticity medications during course of the study~* Ankle plantarflexion contracture greater than 0 degrees~* Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study~* Has had treatment with botulinum toxin of any serotype to RF or gastrocsoleus up to 12 months prior to enrollment in study~* Evidence of current alcohol or drug abuse or history of neuropsychiatric condition not related to ABI~* Concurrent participation in another investigational drug or device study up to12 months prior to enrollment in study~* Infection or skin disorder at an anticipated injection site~* Uncontrolled clinically significant medical condition other than the condition under evaluation~* Known allergy or sensitivity to any of the components in the study medication, including human serum albumin and sodium chloride as well as the botulinum toxin protein~* Any medical condition that may put the subject at increased risk with exposure to BOTOX including, but not limited to, diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, peripheral neuropathy or any other disorder that might interfere with neuromuscular function~* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline injection (Type: PLACEBO_COMPARATOR): None
- Botulinum toxin injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues